European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologists point of view

We read with great interest the new European League against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for systemic lupus erythematosus (SLE) by Aringer et al,1 that recommend a positive antinuclear antibody (ANA) test as an entry criterion for SLE

Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial by Tanaka et al

We have read with interest the paper of Tanaka et al1 and support the need for a more personalised approach in dosing regimens of tumour necrosis factor (TNF) inhibitors.2 They adjusted infliximab dose based on TNF concentrations at baseline, under

Exploring the macro-level, meso-level and micro-level barriers and facilitators to the provision of good quality early inflammatory arthritis (EIA) care in England and Wales

Background Evidence from a national clinical audit of early inflammatory arthritis (EIA) shows considerable variability between hospitals in performance, unexplained by controlling for case-mix. Objective To explore the macro-level, meso-level and micro-level barriers and facilitators to the provision of good

Atopic Dermatitis

Atopic dermatitis is one of the most prevalent inflammatory skin diseases. It usually develops in childhood and may persist into adulthood; less frequently, it starts in midlife or late life. The disorder is characterized by recurrent, pruritic, localized eczema, often

Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics

Early scientific and public enthusiasm for hydroxychloroquine (HCQ) as a potential therapy for COVID-19 has prompted over 100 registered trials to date, although its efficacy remains to be demonstrated.1 Unfortunately, accelerated demand for HCQ has the potential to diminish supplies

Osteoarthritis of the Knee

Foreword. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author’s clinical recommendations. Stage.

Looking for the Outsider

Foreword. In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and reasoning with the reader (regular type). The authors’ commentary follows.

Does socioeconomic status make a difference? A register-based study on the extent to which cardiovascular screening in patients with inflammatory arthritis leads to recommended follow-up in general practice

Objective To investigate to what extent patients with inflammatory arthritis (IA) follow recommendations given in a secondary care nurse-led cardiovascular (CV) risk screening consultation to consult their general practitioner (GP) to reduce their CV risk and whether their socioeconomic status

Trigeminal Neuralgia

Trigeminal neuralgia, traditionally called tic douloureux, is a chronic neuropathic pain disorder characterized by spontaneous and elicited paroxysms of electric shock–like or stabbing pain in a region of the face. A poor quality of life and suicide in severe cases

Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients

European League Against Rheumatism (EULAR) recommendations for cardiovascular (CV) risk management in patients with Rheumatoid Arthritis (RA) suggest to ‘measure cholesterol and other lipid fractions when disease activity is stable or in remission’.1 This point ensues from the assumption that

Facing Uncertainty

Foreword. In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and reasoning with the reader (regular type). The authors’ commentary follows.

Double Trouble

Foreword. In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and reasoning with the reader (regular type). The authors’ commentary follows.

A Terminal Event

Foreword. In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and reasoning with the reader (regular type). The authors’ commentary follows.

A Terminal Event

Foreword. In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and reasoning with the reader (regular type). The authors’ commentary follows.

Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study

Objective This analysis explored the association of treatment adherence with beliefs about medication, patient demographic and disease characteristics and medication types in rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) to develop adherence prediction models. Methods The population

Elephant in the room

We read with interest the article by Aggarwal et al on repository corticotropin injection (RCI) in the treatment of refractory polymyositis and dermatomyositis (PM and DM) published in the Annals of the Rheumatic Diseases.1 The authors, who are well-respected researchers

Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis. Comment on ‘Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis by Jonsson et al

We have read with great interest the article by Jonsson et al that was recently published online in ARD,1 which suggested that calprotectin, also known as S100A8/S100A9 heterodimer, was associated with radiographic progression in early rheumatoid arthritis (RA). Calprotectin correlates

Response to: ‘2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?’ by Malaviya

We are grateful for the insightful and highly relevant question raised by Dr Malaviya1 concerning the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. The question concerns

Response to: Comment on lAmi et al titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial by den Broeder et al

We thank den Broeder et al for their interest in our study and for their suggestions concerning further research.1 Our study did not target the broad issue of dose tapering, but focused on the population of patients with rheumatoid arthritis

Comment on lAmi et al titled Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’

We have read the recent paper of l‘Ami et al titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’ with interest.1 The topic of dose tapering is an

WhatsApp WhatsApp'tan Bize Yazın